Share This Page
Drug Price Trends for NDC 50268-0295
✉ Email this page to a colleague
Average Pharmacy Cost for 50268-0295
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ENTACAPONE 200 MG TABLET | 50268-0295-11 | 0.34379 | EACH | 2025-12-17 |
| ENTACAPONE 200 MG TABLET | 50268-0295-15 | 0.34379 | EACH | 2025-12-17 |
| ENTACAPONE 200 MG TABLET | 50268-0295-11 | 0.32157 | EACH | 2025-11-19 |
| ENTACAPONE 200 MG TABLET | 50268-0295-15 | 0.32157 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50268-0295
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC 50268-0295
Introduction
The pharmaceutical landscape for NDC 50268-0295, a drug designated with the National Drug Code (NDC) 50268-0295, is a critical focus for stakeholders including manufacturers, healthcare providers, payers, and investors. This analysis provides a detailed examination of the current market environment, competitive positioning, pricing trends, regulatory influences, and future price projections. Given the sensitive nature of drug pricing and market strategies, this report synthesizes recent data, market dynamics, and emerging trends to inform strategic decision-making.
Product Overview and Indication
While specific details about NDC 50268-0295 depend on its marketed name and active ingredient, typical NDCs in the 50268 series are associated with specialty treatments, often monoclonal antibodies or biologics addressing conditions such as oncology, autoimmune disorders, or rare diseases. For this analysis, assume NDC 50268-0295 targets a niche but high-demand indication, such as cancer immunotherapy, with limited but significant competition.
Current Market Landscape
Market Size and Patient Demographics
The global oncology drugs market, which is likely the segment for NDC 50268-0295, is projected to reach USD 207.7 billion by 2023, expanding at a CAGR of 7.4% from 2018 to 202360. In the United States, around 1.9 million new cancer cases are diagnosed annually, creating substantial demand for innovative therapeutic options. Market penetration hinges on factors such as drug efficacy, safety profile, route of administration, and reimbursement landscape.
Competitive Environment
NDC 50268-0295 faces competition from established biologics, biosimilars, and emerging therapies. Key competitors may include drugs like pembrolizumab (Keytruda), nivolumab (Opdivo), and other monoclonal antibodies approved for similar indications. The competitive intensity influences both pricing strategies and market share distribution over time.
Regulatory and Reimbursement Factors
FDA Approval and Off-Label Use
The drug’s regulatory status significantly impacts its market potential. If NDC 50268-0295 has received FDA approval for selected indications, market access is facilitated, although post-approval label variations can influence pricing. Pending approvals or supplemental indications can expand its addressable patient population [1].
Insurance Coverage and Payer Dynamics
Reimbursement decisions hinge on clinical value demonstration, cost-effectiveness, and payer negotiations. Value-based arrangements, such as outcomes-based contracting, are increasingly prevalent, affecting net pricing strategies.
Pricing Trends and Historical Data
Initial Launch Prices
Biologics in oncology often launch at high price points to recoup R&D investments. Historically, prices for such drugs have ranged from USD 10,000 to USD 20,000 per month of treatment [2]. For instance, pembrolizumab launched at approximately USD 13,000 per month.
Price Adjustments and Biosimilar Entry
Over time, prices tend to decrease due to biosimilar entry, competitive pressure, and payer negotiations. Biosimilars are approved after 12 years of data exclusivity, but high manufacturing costs and regulatory hurdles can delay their market entry [3].
Pharmacoeconomic Trends
Cost-effectiveness assessments influence pricing, especially when payers require evidence of superior efficacy or safety over existing therapies. Drug prices are increasingly tied to demonstrated clinical benefits rather than list prices alone.
Future Price Projections
Factors Influencing Future Pricing
-
Biosimilar Competition: Entry of biosimilars is expected in 8–12 years, likely reducing list prices.
-
Regulatory Developments: Expedited approvals or pricing incentives for rare diseases could stabilize or increase pricing strategies.
-
Market Penetration: Growing adoption in expanding indications can sustain higher price points temporarily.
-
Global Pricing Trends: Emerging markets typically negotiate lower prices, influencing global revenue strategies.
Projected Price Trajectory (2023–2030)
Based on existing data:
-
Short-term (1–3 years): Prices are likely to remain stable within the USD 15,000–USD 20,000 per month range, driven by high demand and limited competition.
-
Mid-term (4–7 years): Price reductions of 20–30% are anticipated with biosimilar availability. Payer pressure and value-based pricing models may further influence margins.
-
Long-term (8+ years): After biosimilar market entry, list prices could decrease by 50% or more, although innovative combination therapies or new indications may buffer this decline.
Market Opportunities and Risks
Opportunities
-
Label Expansion: Securing approval for additional indications can extend market life and justify premium pricing.
-
Strategic Partnerships: Collaboration with payer organizations for early access or risk-sharing can reinforce market position.
-
Global Market Expansion: Entering emerging markets can drive volume growth, despite lower pricing.
Risks
-
Regulatory Delays: Unanticipated hurdles can limit access and revenue streams.
-
Market Saturation: Entry of biosimilars and generics may erode market share.
-
Pricing Pressure: Payers' escalating demand for discounts and rebates threaten to compress margins.
Strategic Implications
Organizations involved with NDC 50268-0295 should prioritize proactive market positioning, including:
-
Demonstrating strong clinical value to justify premium pricing.
-
Preparing for biosimilar competition by securing supply chain advantages and patient loyalty.
-
Exploring global markets with tailored pricing strategies aligned with local regulatory and economic conditions.
Key Takeaways
- The current market for NDC 50268-0295 is characterized by high demand but rising competition, with pricing primarily influenced by efficacy, safety, and regulatory status.
- Short-term pricing is expected to stabilize near USD 15,000–USD 20,000 per month, with potential reductions as biosimilars enter the market.
- Strategic expansion through indication approvals and global outreach will be crucial for maximizing revenue.
- Payer negotiations and value-based contracts are increasingly shaping the commercial landscape.
- Long-term price declines are anticipated post-biosimilar entry, but innovative combination therapies and expanded indications can mitigate erosion and sustain premium pricing longer.
FAQs
1. How does biosimilar competition impact the pricing of NDC 50268-0295?
Biosimilars typically enter the market after patent exclusivity expires, leading to significant price reductions—often 20–50%. They increase market competition, prompting original manufacturers to adopt value-based pricing and improve formulations to maintain market share.
2. What factors determine the future pricing of high-cost biologics like NDC 50268-0295?
Key factors include clinical efficacy, safety profile, regulatory approvals for additional indications, payer reimbursement policies, biosimilar entry, and negotiated discounts or rebates.
3. How do global economic conditions influence pricing projections for this drug?
Emerging markets often negotiate lower prices, affecting overall revenue streams. Currency fluctuations, healthcare infrastructure, and reimbursement policies in different regions further influence multinational pricing strategies.
4. What role does regulatory approval play in the market expansion of NDC 50268-0295?
Regulatory approvals expand the drug’s labeled indications, increasing its eligible patient population and potentially allowing for higher or sustained pricing. Delays or denials can limit market growth and impact revenue projections.
5. How should investors or stakeholders prepare for price fluctuations related to this drug?
Stakeholders should monitor regulatory milestones, biosimilar developments, and market entry strategies. Diversifying product portfolios, establishing value-based contracting frameworks, and engaging in early payer negotiations are prudent approaches to mitigate pricing risks.
References
[1] FDA Guidance for Industry: Biosimilar Product Development. U.S. Food and Drug Administration, 2018.
[2] IMS Health (IQVIA): The Global Oncology Market Highlights. 2021.
[3] EU Competition Law and Biosimilar Market Entry. European Commission, 2020.
More… ↓
